Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...
In an interesting and timely editorial, Borgland and Neyens provide a snap shot of preclinical research that could support the development of psyche delic drugs as part of a therapeutic regimen in individuals with obesity or eating disorders (EDs), including an orexia nervosa (AN) and binge eating disorder (BED).1 The role of the sero tonergic system in appetite was key in the development...